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Abstract
Introduction and Aims. Naloxone is an opioid antagonist used for emergency resuscitation following opioid overdose. Pris-
oners with a history of heroin use by injection have a high risk of drug-related death in the first weeks after prison-release. The
N-ALIVE trial was planned as a large prison-based randomised controlled trial (RCT) to test the effectiveness of naloxone-
on-release in the prevention of fatal opiate overdoses soon after release. The N-ALIVE pilot trial was conducted to test the
main trial’s assumptions on recruitment of prisons and prisoners, and the logistics for ensuring that participants received their
N-ALIVE pack on release. Design and Methods. Adult prisoners who had ever injected heroin, were incarcerated for
≥7 days and were expected to be released within 3 months were eligible. Participants were randomised to receive, on liberation,
a pack containing a single ‘rescue’ injection of naloxone or a control pack with no naloxone syringe. The trial was double-blind
prior to prison-release. Results. We randomised 1685 prisoners (842 naloxone; 843 control) across 16 prisons in England.
We stopped randomisation on 8 December 2014 because only one-third of administrations of naloxone-on-release were to the
randomised ex-prisoner; two-thirds were to others whom we were not tracing. Discussion and Conclusions. Prevention
RCTs are seldom conducted within prisons; we demonstrated the feasibility of conducting a multi-prison RCT to prevent fatal-
ity from opioid overdose in the outside community. We terminated the N-ALIVE trial due to the infeasibility of individualised
randomisation to naloxone-on-release. Large RCTs are feasible within prisons. [Meade AM, Bird SM, Strang J, Pepple T,
Nichols LL, Mascarenhas M, Choo L, Parmar MKB. Methods for delivering the UK’s multi-centre prison-based
naloxone-on-release pilot randomised trial (N-ALIVE): Europe’s largest prison-based randomised controlled trial.
Drug Alcohol Rev 2018;37:487–498]
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Introduction
Naloxone is an opioid antagonist used by emergency
services to reverse heroin/opioid overdose [1]. Prison-
ers with a history of heroin injection have a high risk of
drug-related death (DRD) soon after prison-release
which was estimated at 5 DRDs per 1000 eligible
releases on the basis of record-linkage studies in Scot-
land in 1996–1999, and in England and Wales in
1999–2002 [2,3]. The definitive N-ALIVE trial was
planned as a large prison-based randomised controlled
trial (RCT) to test the effectiveness of naloxone-on-
release (NOR) in the prevention of fatal opioid over-
doses soon after release. The N-ALIVE pilot trial was
a randomised feasibility study.
Internationally, a number of RCTs of public
health, medicinal or nutritional interventions have
been carried out in prisons. Those investigating the
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management of opioid addiction include an RCT in
Australia in the late 1990s [4], three in the UK in the
late 1990s, 2004–2005 and 2006–2008, respectively
[5–7], one in Norway from 2005–2007 [8] and one in
the USA in the 21st Century [9]. The number of pris-
oners randomised ranged from 382 prisoners in the
Australian trial, 283 in the US trial, 46 in the Norwe-
gian trial and 68, 90 and 306, respectively in the RCTs
conducted in UK prison(s).
N-ALIVE, however, is the largest multi-centre,
prison-based interventional RCT in Europe and to our
knowledge, including a recent systematic review by
Kouyoumdjian et al., the largest RCT conducted in
prisons worldwide [10]. N-ALIVE is also unique in
that it is a trial of a prison-based intervention which is
delivered to prevent fatalities in the community.
Because the intervention in N-ALIVE was deemed
by some as contentious, by others as complex [11] and
because of the prison setting, it was imperative that the
highest standards of governance be adhered to
throughout N-ALIVE’s conduct. On principle and in
practice, participants who are prisoners should not be
excluded from participating in RCTs. Prison-based
RCTs, on the other hand, must address either a con-
cern that applies specifically to prisoners—to counter
the challenge that the same trial could equally well
have been conducted in the outside community; or be
able to point to parallel RCTs on the outside to answer
the challenge of exploiting prisoners’ captivity. Sensi-
tive to these issues, the N-ALIVE trial program was
designed to provide a robust evidence-base on redu-
cing prisoners’ DRDs soon after release.
Originally, N-ALIVE was planned as a UK-wide
study. N-ALIVE did not proceed in Scotland because,
in January 2011, Scotland became the first nation to
make take-home-naloxone in the community, and
NOR for eligible prisoners at liberation, a funded pub-
lic health policy [12,13]. Wales followed suit later in
2011 [14]. N-ALIVE therefore restricted its geographi-
cal scope to England where no such centrally funded
public policy decision had been made.
This paper focuses on the methods of trial conduct
for the N-ALIVE pilot trial. The background, rationale
and objectives for the trial and the feasibility outcome
results are described separately in two publica-
tions [15,16].
Methods
Trial design (planned for England and Wales;
and Scotland)
The N-ALIVE pilot trial design, sample size calcula-
tions, data collection, eligibility, consent and
randomisation processes, N-ALIVE packs, returned
prisoner self-questionnaire, primary and secondary out-
comes and statistical analysis plan are described in Par-
mar et al. [16] and in the N-ALIVE protocol published
on the Medical Research Council (MRC) Clinical Trials
Unit (CTU) website [17]. The trial design is sum-
marised in Figure 1. In brief, eligible consenting partici-
pants were randomised (1:1) to receive, at liberation, a
pack containing either a single ‘rescue’ injection of nal-
oxone (an opioid agonist) or a control pack which did
not contain naloxone. The trial was double-blind up
until the point of release so that neither the participant
nor prison-based N-ALIVE staff nor prison staff knew
the allocation while the participant was in custody. Parti-
cipants learned their allocation when they opened the
pack immediately after their release from prison.
The trial included a randomised sub-study in which
participants who gave consent for once-only tele-
phone contact after release were randomised further
between no contact and telephone contact in the first
versus second fortnight after release in the ratio of
2:1:1. The rationale for the 50% no-contact-rate was
to minimise contamination of the main randomisation
as the telephone-interview asked participants, inter
alia, if they were carrying naloxone—in effect,
reminding them to do so.
In addition, an optional consent enabled former
N-ALIVE participants who returned to prison within
6 months of their most recent N-ALIVE release to
be invited to complete a Returned Prisoner Self-
Questionnaire (RPSQ): 85% of randomised participants
consented (1417 of 1676). Using the RPSQ, we collected
information about naloxone carriage, its administration
and heroin use after release from prison [16].
User and service engagement
During the trial design stage, the trial’s co-principal
investigators (PI) met with prisoners with a history of
heroin injection. A number of prisoners took part at
each of two prisons, one in Scotland and one in Eng-
land. Prisoners’ feedback informed planning of the
trial’s logistics and conduct. For example, a prisoner
illustrated to the PIs the size of a small tin that, on
liberation, would contain all of his valuable posses-
sions (which were few). This led to a desire for a nal-
oxone kit which would be no larger than the size of a
credit card which led in turn to the decision to con-
tain the naloxone kit within a wallet. Organisations
and others who work with heroin users, such as
SPODA (an organisation supporting families and
carers of drug misusers) and families against drugs
also contributed to the trial design, including the N-
ALIVE DVD [18,19].
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Trial set-up (England only)
National approvals
Figure 2 lists the many approvals that had to be
obtained in order to get N-ALIVE pilot trial up and
running.
Links with the mental health research network
The English Mental Health Research Network
(MHRN) adopted the N-ALIVE pilot trial into its
portfolio of studies, and thus supported us in setting
the trial up at prison sites and provided clinical studies
officers to perform the role of prison-based N-ALIVE
worker at many of our prisons.
Prison selection and local approvals
We approached 20 large prisons holding prisoners of
security category B (no need for high security condi-
tions) and C (for prisoners not trusted with open con-
ditions, but unlikely to make a determined escape
attempt). MHRN co-ordinators also suggested prisons
in their network area that might be suitable.
We began visiting prisons in February 2011. The
trial was designed to cleave to prison procedures, yet
within each prison we encountered different methods
of operation. It took 13 months to get approval from
the first prison and a further 3 months before they
opened to participant accrual. Reasons for delays in
prison set-up included the lengthy process to agree,
obtain and issue research and development approval,
appointing N-ALIVE workers (often delayed for fund-
ing reasons) and obtaining their security clearance,
agreeing the pack prescription method and completing
and collating trial accreditation documents.
In most cases, the preferred first step with each
prison was a meeting at the prison with as many stake-
holders as possible (a person of Governor grade, secu-
rity and health-care representatives, and, if possible, a
candidate for the N-ALIVE worker role). During these
meetings, the rationale for the trial was presented and
details of how the trial might be conducted were intro-
duced; questions about the trial were answered and
any concerns discussed. A PI was identified to lead the
research team at each prison. See Figure 3 for a map
of N-ALIVE prisons and MHRN hubs.
We were unsuccessful in our attempts to engage
with a number of prisons because of security concerns,
workload issues and even prison organisational
Figure 1. N-ALIVE pilot trial design.
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changes, for example, re-rolling of prison category or
possibility of closure or privatisation. At one prison,
short-term funding via National Health Service (NHS)
England’s ‘Through the prison gateway’ scheme led to
their own non-randomised take-home-naloxone pro-
gram shortly after they had been approved to partici-
pate in the N-ALIVE pilot trial.
N-ALIVE DVD
We produced an instructional film on DVD which we
also posted on YouTube and on the trial web-page
[19]. The film had a three-part structure: (i) ‘The N-
ALIVE Heroin Overdose Study’; (ii) ‘What’s in the
Pack?’; and (iii) ‘Giving the Naloxone’. The DVD was
provided to all participants in their N-ALIVE pack
(both naloxone and control) and they were encouraged
to share its viewing with family and friends.
The N-ALIVE worker role
A key role in each prison was that of the N-ALIVE
worker. Their responsibilities included identifying
potentially eligible participants, explaining the trial, tak-
ing consent, randomising, completing case report forms
and ensuring that participants received their packs on
release; all the while maintaining close links with MRC
CTU and with prison staff. In some prisons, the N-
ALIVE worker role was undertaken by the MHRN clin-
ical studies officers and/or staff seconded from other
health-care roles in the prison. These posts were funded
by the MHRN or by the Comprehensive Local
Research Network in which the prison was located.
We provided trial-specific training to N-ALIVE
workers, usually face-to-face. Once one person at a
prison site received training, he/she could train other
colleagues at that prison. N-ALIVE workers also com-
pleted Good Clinical Practice training and were
advised to watch the N-ALIVE DVD.
Prison-specific training
N-ALIVE workers had to have hepatitis B immunisa-
tion, Criminal Record Bureau security clearance and
undertook key training before they could have access
to the prison.
N-ALIVE packs: choice of naloxone product and
description of other contents
The N-ALIVE co-PIs agreed that naloxone should be
provided as an intramuscular injection (which does not
National Approvals: 
• NHS/HSC Research and Development approval*  
• Research Ethics Committee Approval – Type 1 REC (Reference 10/H0302/6)*  
• Ministry of Justice National Offender Manage ment System’s National Research Committee  
• Mental Health Research Network – adoption into approved portfolio of trials 
Local Approvals: 
• Local Research and Development approval  
• Governor grade approval (including signed agreement) 
• Signed Patient Group Directive or Patient Specific Directive  
• Completed delegation log and contact details for all staff working on the trial at each prison  
• Local working instructions/guidelines for N-ALIVE workers 
• CVs of investigators and co-investigators 
• Training record for site staff 
Figure 2. National and local approvals for N-ALIVE. *If the N-ALIVE pilot trial were being conducted today we would apply for
approvals through the Health Research Authority process. HSC, Health and Social Care; NHS, National Health Service.
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require the specialist skills required for intravenous
injection) and preferably in a syringe pre-loaded with
naloxone (and therefore ready to be administered with-
out any further preparation).
Three pharmaceutical formulations of naloxone
existed on the UK market at the time of trial planning:
first, a traditional glass ampoule of naloxone 0.4 mg;
second a pre-filled special Mini-Jet syringe of 0.4 mg
and third a pre-filled standard syringe of 2 mg. None
of these formulations contained the correct identified
dose of 0.8 mg, and none had a stake needle
(moulded/fixed needle). It became clear that a stake-
needle variant would only be available to the N-ALIVE
trial team as a ‘special’ preparation which would
render the medication an investigational medicinal
product which would have additional implications for
trial conduct. The option of giving the N-ALIVE
participant two 0.4 mg ampoules or mini-jets was
ruled out because of the risk of contamination between
the intervention and control groups; a participant leav-
ing prison with two ampoules or mini-jets could give
one of them to a fellow released prisoner who had been
assigned to the control group. Thus, the naloxone
needed to be a single product for the purpose of the
trial. None of the available products fitted our needs
perfectly, but we concluded that a sufficient dose in
single product form was most crucial. Accordingly, we
selected the 2 mg pre-loaded syringe as an acceptable
formulation, in which there is more than adequate
dose. This choice of dose necessitated additional
instructions for administration to be limited to a
0.8 mg dose. We therefore developed instructions, and
the DVD and YouTube contributions to teach the
administration of a 0.8 mg dose from the 2 mg pre-
Figure 3. Map of N-ALIVE prisons and the Mental Health Research Network hubs.
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filled syringe formulation and safe disposal of the
syringe to avoid its reuse for another person. The
method of naloxone delivery, including the choice of
dose is also described in Strang et al. [15]. The
N-ALIVE packs are described in Parmar et al. [16]; a
picture of the naloxone wallet is shown in Figure 4.
We entered into correspondence with the UK Medi-
cines and Healthcare Regulatory Agency to confirm
that the trial was not a clinical trial of an investigational
medicinal product. The Medicines and Healthcare
Regulatory Agency accepted that the outcomes of the
pilot trial were not related to the drug efficacy, safety,
metabolism or pharmacodynamics, or indeed, to the
drug in anyway, but concerned the treatment manage-
ment strategy only. Naloxone was being used within
its license and we would not be gaining any further
information about the authorised form.
The rationale for providing both groups with a
sealed N-ALIVE pack (box) containing the wallet at
the point of prison-release was in order to preserve the
double-blind assignment up until the point of libera-
tion. This safeguarded prisoners from undue pressure
from peers while in custody; and ensured that
N-ALIVE workers could not subconsciously or delib-
erately support or add precautionary measures or
behave differently towards those prisoners who had
been assigned to the control group. A common stand-
ard of care-as-usual therefore applied until the point of
release when the ex-prisoners were given their
allocated N-ALIVE pack and opened it to discover
their allocation.
Getting packs to prisons
Once a prison was approved to participate in the pilot
trial, a stock of pre-numbered N-ALIVE packs was
issued to it. N-ALIVE packs were stored securely
within prison pharmacies or in an alternative secure
location. We provided lockable cabinets to prisons on
request.
Prescribing naloxone
In consultation with their local NHS trust, research
teams at the prisons chose one of two procedures for
prescribing naloxone to participants: the patient spe-
cific direction (PSD) or the patient group direction
(PGD). A PGD is a legal document which allows
registered doctors, nurses or pharmacists to prescribe a
product without the need for individual prescriptions
so long as they have received training on the PGD.
Once a PGD has been approved there is no additional
paperwork to complete for individual participants.
A PSD is a written instruction from a qualified, regis-
tered prescriber for a medicine, including the dose,
Figure 4. The N-ALIVE naloxone wallet. N-ALIVE trial wallet containing the naloxone-filled syringe and needle,
information on overdose management and ‘authorisation to carry’ card.
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route and frequency to be supplied to a named patient.
A PSD was generally used when the N-ALIVE worker
was not a qualified prescriber. A separate entry was
made on the PSD form and signed off by the local PI
prior to randomisation of each participant. Because the
trial was double-blind until the participants opened
their pack on release, the same procedures were fol-
lowed for all participants whilst in prison. Consequently
all packs were documented on the PGD/PSD irrespec-
tive of whether they contained naloxone or control, as
staff would have been unaware of pack contents.
Trial oversight
A Trial Management Group (TMG) was formed by the
three co-PIs and the MRC CTU trial team who were
responsible for the day-to-day management of the trial.
The TMG met (usually monthly) either in person or via
teleconference, or discussed issues via email as appro-
priate. The very broad remit of the TMG was to man-
age the trial, including the clinical and practical aspects.
We established a joint Trial Steering and Data Mon-
itoring Committee (TS-DMC); the committee paid
particular regard to accrual and changes in national
policy which might impact on the continuing need for
the N-ALIVE main trial. The latter was important
because we had given an undertaking to participants
and to the Research Ethics Committee (REC) that
recruitment to the N-ALIVE pilot trial would cease if
we had reason to know that the main trial could not go
ahead. The committee met on five occasions during
the feasibility trial. We developed Charters for both the
TMG and TS-DMC which were agreed and signed by
all members.
Confidentiality
With their explicit consent, participants’ name, date of
birth, sex and NHS number were disclosed to us to
enable database linkages to inform the trial’s outcome
measures. Participants’ names were stored separately
from the other information held about them.
All consent forms and copies of case report forms
were stored securely within the prison. Copies of the
consent form were sent to MRC CTU to be checked
and were then destroyed. To encourage frankness,
completed RPSQs identified only the participant’s
treatment assignment in N-ALIVE pilot trial, the
month and year of their most recent N-ALIVE release,
and the month and year of RPSQ completion.
Participants who consented to the telephone contact
sub-study were asked to provide up to two telephone
contact numbers: 56% of participants consented to the
sub-study (946 out of 1676 randomised); 95%
confidence interval 54%–59%. The telephone numbers
were stored in separate secure databases. At the initia-
tion of the telephone call, we did not disclose that the
participant was an ex-prisoner or that N-ALIVE aimed
to reduce DRDs. Eighty-one interviews were success-
fully conducted.
Systems and databases at MRC CTU at UCL
We used an in-house randomisation system which we
linked to our database inventory of N-ALIVE packs.
When unassigned packs at a prison reached a certain
threshold, an email was generated and used to inform
the pack distribution company about which additional
trial packs to supply to that prison.
The database for managing the clinical trial data was
developed and managed in-house using MACRO ver-
sion 4. A separate database was developed as a repository
for data from the RPSQ and telephone questionnaires.
Trial conduct during recruitment
Identifying potential participants
N-ALIVE workers liaised with members of the health
care/addictions staff at their prison to find the best
approach for identifying potential participants. Self-
referral was encouraged and posters advertising the
trial were provided for display in the wings, health
care, methadone-dispensary, reception and visiting
areas. Word-of-mouth communication between pris-
oners about the trial was widely reported by our
N-ALIVE workers.
Participant information and informed consent
Our prior logistical plan was that potentially eligible
prisoners would learn about the trial in group sessions
for six to eight prisoners who could then request a
one-to-one individual consent session. In practice,
group sessions were not feasible in most prisons due to
unavailability of private space or restrictions on pris-
oner movement.
We produced a summary and a full patient informa-
tion sheet. The summary patient information sheet
could be provided when prisoners initially expressed
interest in the trial. The full patient information sheet
could also be given at this point or held in reserve until
the potential participant had time to digest the initial
information. Potential participants could take as long
as they needed to consider whether or not to take part
in the trial. If the N-ALIVE worker had any concerns
about a prisoner’s comprehension of the trial, he/she
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encouraged to discuss his/her concerns with a member
of the health-care team prior to obtaining consent.
Randomisation
To randomise a participant, the N-ALIVE worker con-
tacted the MRC CTU by telephone. Once the
patient’s eligibility was confirmed, the N-ALIVE
worker was provided with the participant’s pack num-
ber. This pack number was the participant’s unique
identifier in the trial (‘trial number’). The randomisa-
tion method (80:20 minimisation) is described in Par-
mar et al. [16].
Shortfall in accrual
Despite being the largest European prison-based inter-
ventional trial to date, we did not meet our accrual tar-
get of 2800 prisoners from English prisons. The
original protocol target was up to 10% of the number
of patients required for the main trial; the target was
reduced to 2800 when the N-ALIVE pilot trial could
randomise in English prisons only. The justification
for the original sample size is described in Parmar et al.
[16]. Between 28 May 2012 and 8 December 2014,
we randomised 1685 participants (842 to naloxone,
843 to control) [16] (Figure 5). The reticence to ran-
domise remand prisoners (who have court appearances
to make) was a factor in reduced accrual, as was insuf-
ficient N-ALIVE worker time at prisons. Other reasons
included: slower than anticipated set-up time for new
prisons, fewer prisoners with a history of heroin injec-
tion, outdated prior estimates based on prisons’ drug
treatment clients in 2005 and some potential partici-
pants who, because they wanted to move away from
opiate use, worried that carrying naloxone might be
interpreted by family and friends as a lack of resolution.
Slower than anticipated accrual meant that the stock
of naloxone we ordered at the start of the trial expired
Did not meet inclusion criteria (n= 84)
Eligible (n=1777)
Did not consent (n= 494)
- 114 (23%) did not wish to return to 
previous lifestyle 
- 119 (24%) other reasons including 
insufficient time for consent before 
release/transfer
- 227 (46%) not interested
- 34 (7%) no reason reported 
Analysed  Intention-to-treat (ITT) (n=783)
¨ Excluded from ITT analysis*  (n=48)
Analysed Per Protocol (PP) (n=666)
¨ Excluded from PP analysis* * (n=175)
Still in Custody: (n=10)
- Up to & including 1yr from randomisation (n=4)
- More than 1 year from randomisation (n=6)
Allocated to Control intervention (n=841)
¨ Received allocated intervention (n=666)
¨ Did not receive allocated intervention (n=148)
- Unknown if allocated intervention received (n=27)
Released before recruitment closure (n=783)
Released after recruitment closure (n=48)
Still in Custody: (n=20)
- Up to & including 1yr from randomisation (n=11)
- More than 1 year from randomisation (n=9)
Allocated to Naloxone intervention (n=835)
¨ Received allocated intervention (n=659)
¨ Did not receive allocated intervention (n=158)
- Unknown if allocated intervention received (n=18)
Released before recruitment closure (n=774)
Released after recruitment closure (n=41)
Analysed  ITT (n= 774)
¨ Excluded from ITT analysis* (n=41)
Analysed  PP (n=659)
¨ Excluded from PP analysis**  (n=176)
Allocation
Analysis
Follow-Up
Randomized (n= 1685 )
Enrolment Assessed for eligibility (n>2355)
Randomised in error (n=5) 
- (Error at Site) (n=1)
- Release date beyond 3 months (n=4)
Withdrew consent for mortality FU (n=4)
- No history of heroin use (n=1) 
- Poor state of mental health (n=1) 
- No reason given (n=2) 
Randomized and eligible for analysis (n= 1676 )
Figure 5. CONSORT diagram (originally published in Parmar et al. [16]). Screening records have only been kept since September 2012 so
only provide a snapshot of the proportions deemed eligible and subsequently randomised. *Excluded from ITT analysis participants released
after recruitment closure (n = 48, 40). **Included in PP analysis participants released with pack only.
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before it could be used and consequently we needed to
purchase new stock and replace the soon to be expired
stock. Both naloxone and control N-ALIVE packs at
sites were replaced to preserve the integrity of the blind
allocation.
Participant data
N-ALIVE workers provided data on paper case report
forms; completed case report forms were sent to MRC
CTU at UCL via fax or post.
Storing and getting packs to participants on release
Prisoners routinely receive their valuable property
and/or medication as they are released from prison or
from court and these valuables are transferred with
them if they change prison. In theory, N-ALIVE would
cleave to this process, and once allocated by randomi-
sation, the participant’s N-ALIVE pack would be
placed with his/her valuable property. In practice, stor-
age of the N-ALIVE pack with the prisoner’s valuable
property was not always possible for a variety of rea-
sons generally relating to security concerns. Trustee
prisoners in some prisons had a degree of access to val-
uable property (and half the N-ALIVE packs contained
a needle) while, in other prisons, there were concerns
that prisoners would get access to a needle before they
had properly exited the prison on the day of their
release. Another concern was a misconception that
provision of an N-ALIVE pack by security staff to a
participant on their release might constitute secondary
prescribing. As prisons gained experience, increasing
numbers of prisons allowed packs to be placed in pris-
oner’s valuable property.
N-ALIVE workers worked around the embargo on
placing packs in valuable property and made alterna-
tive arrangements for prisoners whom they were
expecting to be released or transferred. However, pris-
oners are often released, returned to court or trans-
ferred at very short notice. If a participant was
transferred to another N-ALIVE prison, then the trial
team or the N-ALIVE worker could often arrange
transfer of the prisoner’s allocated pack retrospectively,
but this was much more difficult if participants were
transferred to non-N-ALIVE prisons as we did not
have the contacts to facilitate pack transfer. There were
exceptions, staff at a number of non-N-ALIVE prisons
accepted N-ALIVE packs as participant prisoners’
property. Unfortunately, even after successful transfer
to non-N-ALIVE prisons, we were often unable to
confirm whether participants had received their packs
when they were eventually released.
Obtaining personal outcome data from national registries
Formal approval was obtained from the Office for
National Statistics for the provision of mortality data.
We obtained matched mortality data on N-ALIVE trial
participants using a secure data transfer process.
Results are described in Parmar et al. [16].
Communicating with N-ALIVE workers, prisons and
prisoners
To ensure timely answering of queries from N-ALIVE
workers, we set-up a trial team email address. We also
set-up an N-ALIVE worker email group and encour-
aged N-ALIVE workers to communicate directly with
each other. Together with the N-ALIVE workers, we
engaged with as many members of prison staff as we
could. In addition to initial training for each site, we
held a well-received N-ALIVE worker and PI meeting
in June 2014 where everyone shared experiences and
best practices. We produced regular newsletters and
we presented trial updates at annual MHRN confer-
ences. N-ALIVE was also featured on prison radio and
in Inside Times, the newspaper for prisoners.
Trial close-out
Early cessation of randomisation
An interim review of the N-ALIVE pilot trials feasibil-
ity outcomes was undertaken to coincide with the
release of official statistics on the third year of Scot-
land’s National Naloxone Programme [21]. Examina-
tion of the responses to the RPSQs identified that only
a third of the emergency naloxone administrations to
reverse overdose were to the randomised ex-prisoner,
two-thirds were to an individual who was not the study
subject [16]. Our data capture methods were not able
to identify, let alone consent, these other individuals.
This finding, which was backed up by the Scottish
results [22], had major implications for the main N-
ALIVE trial, which was designed around individual
randomisation. Consequently, the TS-DMC unani-
mously agreed that randomisation to the N-ALIVE
pilot trial should cease on 8 December 2014 [20]. This
decision was also approved by our appointed REC.
Our TS-DMC also proposed (and the REC-
approved) that, with the approval of the PIs at each
prison, participants who remained in custody on the
morning after accrual stopped should be offered nalox-
one-on-release, irrespective of their randomised alloca-
tion [20]. We produced a letter for trial participants
still in custody to explain these changes; this was also
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REC-approved prior to circulation. We updated our
N-ALIVE web-page with details of all decisions [23].
We communicated both the unplanned closure and
the plan for participants remaining in custody to our
N-ALIVE workers and local PIs by email together with
the reasoning behind the decisions; followed by details
on how to manage the changes.
Final steps at sites
From 19 June 2015, N-ALIVE packs were no longer
provided to participants. All participants were expected
to have been released within 3 months of their rando-
misation; the 19 June cut-off date allowed for another
3 months’ grace. Other factors that influenced this
decision included the expiry date on the naloxone
packs and the fact that many of our N-ALIVE workers
were no longer regularly available. Further data collec-
tion from sites also stopped on this date in compliance
with our protocol (6 months after accrual of the last
participant). Both of these decisions were approved by
our REC and then relayed to our N-ALIVE workers
for execution [24]. N-ALIVE workers also helped pre-
pare sites for overall trial closure. Some sites were una-
ble to archive the trial files for the required 20 years;
files were thus transferred to UCL for storage.
Discussion
We have unequivocally demonstrated the feasibility of
conducting a large randomised trial in multiple pris-
ons. The approval and conduct of the N-ALIVE trial
involved multiple agencies and policy environments,
many of which were subject to considerable change in
the course even of the N-ALIVE pilot trial. Support of
the MHRN was invaluable.
Good communication has been essential. We needed
key members of staff at the prison (Governor, health
care, reception and security staff ) to be aware of the
trial and the trial processes. Most prisons were very
supportive of N-ALIVE and this support generally
increased as prisons gained experience with the trial.
Some prisons were less engaged, but usually this was
because they had competing concerns which took prior-
ity over N-ALIVE. The Governors at our N-ALIVE
prisons understood our objectives and were willing to
work with us; their main concern being the safety, secu-
rity and wellbeing of all their inmates and staff in what
can be a very hectic and challenging environment. Clin-
ical trials are carried out to high standards following
recognised guidelines and procedures; this was reassur-
ing for prisons where rule and order are valued. At one
prison, our N-ALIVE worker was experiencing some
difficulty getting security staff to help with getting packs
to participants on their release. The Governor engaged
with us to document and approve a policy that became
part of routine procedure in that prison. We then
shared this policy with other prisons.
Prisoner approval for the trial was high [16].
N-ALIVE workers reported enthusiasm for the idea
behind the trial even amongst those who decided not
to participate (such as prisoners who had undergone
detoxification and wished to abandon their former life-
style). One of our prisons reported that participants
had asked about having a certificate to say that they
had attended the information groups and were partici-
pating in a trial as they felt that this would be favour-
ably perceived by probation and the courts. Feedback
received from participants during the follow-up tele-
phone calls and in the additional comments section of
the RPSQ was generally positive, insightful and sup-
portive [16]. It was the responses to the questions
about what the participants did with their naloxone
that showed us that individual randomisation was not
appropriate for the main trial and led to the decision to
cease randomising to the pilot trial.
Delayed registration of deaths in England means
research teams like ours who seek to verify the survival-
status of study-participants are informed not about
deaths which have occurred, but about deaths which
have occurred and have been registered as having
occurred. The two differ importantly because the delay
to allow cause of death to be established by inquest and
then registered can be one year or more. For us, this
meant we had to wait to report on the number of DRDs
among our N-ALIVE participants. Similar delays will
be experienced by others until legislation is introduced
to uncouple registration of the fact of death from regis-
tration of the cause of death. This is something Profes-
sor Bird and the UK Royal Statistical Society have
argued for over the last many years [25,26], but
requires legislation which—to date—has not been
brought forward.
Furthermore, the introduction of a unique prisoner
number system across the entire prison population
greatly facilitates research in general. We benefitted
from the unique prisoner numbering system which
enabled the majority of N-ALIVE prisoners to be re-
contacted on re-incarceration. We now need to see this
number system being used across all prisons—private
as well as public.
Conclusions
We have shown that it is possible to successfully con-
duct large-scale randomised trials across multiple pris-
ons. We hope that others will use the N-ALIVE pilot
trial experience as a basis for undertaking more trials
in prisons and other complex environments.
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